Dual Orexin Receptor Antagonists and Suicide Risk: Findings From the WHO Spontaneous Reporting Database

References (6)

1. Geoffroy PA, Oquendo MA, Courtet P, et al. Sleep complaints are associated with increased suicide risk independently of psychiatric disorders: results from a national 3-year prospective study. Mol Psychiatry. 2021;26(6):2126–2136. PubMed CrossRef
2. McCall WV, Benca RM, Rosenquist PB, et al. Reducing suicidal ideation through insomnia treatment (REST-IT): a randomized clinical trial. Am J Psychiatry. 2019;176(11):957–965. PubMed CrossRef
3. Nobile B, Olié E, Courtet P. Possible suicidal risk with daridorexant, a new treatment for insomnia. J Clin Psychiatry. 2022;84(1):22l14628. PubMed CrossRef
4. Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Drug Inf J. 2008;42(5):409–419. CrossRef
5. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315–321. PubMed CrossRef
6. Wang C, Wang Q, Ji B, et al. The orexin/receptor system: molecular mechanism and therapeutic potential for neurological diseases. Front Mol Neurosci. 2018;11:220. PubMed CrossRef